Live Breaking News & Updates on Development Service Revenue

Stay updated with breaking news from Development service revenue. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Candel Therapeutics : Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights - Form 8-K -March 28, 2024 at 07:48 am EDT

Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for. ....

Aljanae Reynolds , Theodore Jenkins , Candel Therapeutics Inc , Exchange Commission , Development Expenses , Drug Administration , Business Development , Society For Immunotherapy Of Cancer , Development Service Revenue , International Oncolytic Virus Conference , Company Nasdaq , Candel Therapeutics Reports Fourth Quarter , Full Year , Recent Corporate Highlights , Track Designations , Track Designation , Paul Peter Tak , Fast Track Designation , High Grade Glioma , Discovery Platform , Fourth Quarter Ended December , Administrative Expenses , Private Securities Litigation Reform Act , Annual Report ,

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in. ....

Aljanae Reynolds , Theodore Jenkins , Development Expenses , Development Service Revenue , Exchange Commission , Company Nasdaq , Candel Therapeutics Inc , International Oncolytic Virus Conference , Society For Immunotherapy Of Cancer , Business Development , Drug Administration , Track Designations , Track Designation , Paul Peter Tak , Fast Track Designation , High Grade Glioma , Discovery Platform , Fourth Quarter Ended December , Administrative Expenses , Private Securities Litigation Reform Act , Annual Report ,

Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Aug. 10, 2023 Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported.
-Today at 08:02 am- MarketScreener ....

United States , Sylvia Wheeler , Aljanae Reynolds , Cancer Foundation , Company Nasdaq , American Society Of Clinical Oncology , American Society Of Gene , Researchanddevelopment Service Revenue , Program Updates , Candel Therapeutics Inc , Drug Administration , Paul Peter Tak , Chief Executive Officer , Non Small Cell Lung Cancer , Track Designation , Clinical Oncology , High Grade Glioma , Cell Therapy , Break Through Cancer Foundation , Nicoletta Loggia , Candel Board , Quarter Ended June , Development Service Revenue , Development Expenses , Consolidated Statements , Discovery Platform ,

Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy Candidates in Solid ....

Cassidy Mcclain , Gary Nabel , Jasona Amello , Patricky Wen , Joseph Papa , Renee Gaeta , Neil Sheppard , Garrett Nichols , Sylvia Wheeler , Silicon Valley Bank , Early Research At Candel , Company Nasdaq , T Cell Engineering Lab , European Commission , Meeting Of The Society For Neuro , Credit Suisse , University Of Pennsylvania Center , Lomb Corporation , Development Service Revenue , Postdoctoral Research , European Medicines Agency , Candel Therapeutics Inc , Dana Farber Cancer Institute , Modex Therapeutics Inc , Study Combinations , Solid Tumor ,